Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: Results from a randomized, double-blind study

Clinical Infectious Diseases

Volumn 33, Issue 7, 2001, Pages 1015-1021

  Overbosch, David ^a   Schilthuis, Herbert ^b   Bienzle, Ulrich ^c   Behrens, Ronald H ^f   Kain, Kevin C ⁱ   Clarke, Paul D ^g   Toovey, Stephen ⁱ   Knobloch, Jürgen ^d   Nothdurft, Hans Dieter ^e   Shaw, Dea ^j   Roskell, Dea ^h   Chulay, Jeffrey D ^j  

^a Harbour Hospital   (Netherlands)

^b MUNICIPAL HEALTH SERVICE   (Netherlands)

^c Institute of Tropical Medicine   (Germany)

^d Hospital for Tropical Diseases   (Germany)

^e TORONTO GENERAL HOSPITAL   (Canada)

^f Medical Advisory Service for Travellers Abroad   (Germany)

^g Republic of South Africa   (Germany)

^h UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

ⁱ Tropical Medicine   (Germany)

^j GLAXOSMITHKLINE   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ATOVAQUONE PLUS PROGUANIL; MEFLOQUINE;

ADOLESCENT; ADULT; AGED; ANXIETY; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ENDEMIC DISEASE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INFECTION RESISTANCE; INSOMNIA; MAJOR CLINICAL STUDY; MALARIA; MALARIA CONTROL; MALE; MULTICENTER STUDY; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; TRAVEL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIMALARIALS; ATOVAQUONE; CHILD; CHILD, PRESCHOOL; CHLOROGUANIDE; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HUMANS; MALARIA; MALE; MEFLOQUINE; MIDDLE AGED; NAPHTHOQUINONES; TRAVEL; TREATMENT OUTCOME;

EID: 0035478615     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/322694     Document Type: Article

References (25)

1. Primary care: health advice and immunizations for travelers
2. Imported malaria (1985-95): Trends and perspectives
3. Imported malaria: Prospective analysis of problems in diagnosis and management
4. Neuropsychiatric side effects after the use of mefloquine
5. Mefloquine prophylaxis: An overview of spontaneous reports of severe psychiatric reactions and convulsions
6. Malaria at Christmas: Risks of prophylaxis versus risks of malaria
7. Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: Postal and telephone survey of travellers
8. Neuropsychiatric adverse effects of mefloquine: What do we know and what should we do?
9. Efficacy and safety of atovaquone/proguanil for suppressive prophylaxis against Plasmodium falciparum malaria
10. Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children
11. A randomized, double-blind, placebo-controlled field trial to determine the efficacy and safety of Malarone (atovaquone/proguanil) for the prophylaxis of malaria in Zambia
12. Researches on paludrine (M.4888) in malaria. An experimental investigation undertaken by the L.H.Q. Medical Research Unit (A.I.F.), Cairns, Australia
13. Prophylactic activity of atovaquone against Plasmodium falciparum in humans
14. Atovaquone and proguanil hydrochloride for prophylaxis of malaria
15. Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: A randomised, double-blind study
16. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine
17. Indirect fluorescent-antibody tests for parasitic diseases. V. An evaluation of a thick-smear antigen in the IFA test for malaria antibodies
18. Trials to assess equivalence: The importance of rigorous methods
19. Side effects of melfoquine prophylaxis for malaria: An independent randomized controlled trial
20. Agreement between microscopical diagnosis and indirect fluorescent-antibody tests in Plasmodium vivax and Plasmodium falciparum infections
21. Fluorescent antibody studies in human malaria. II. Development and persistence of antibodies to P. falciparum
22. Evidence for a 6.5-day minimum exoerythrocytic cycle for Plasmodium falciparum in humans and confirmation that immunization with a synthetic peptide representative of a region of the circumsporozoite protein retards infection
23. Development of immunity in natural Plasmodium falciparum malaria: Antibodies to the falciparum sporozoite vaccine 1 antigen (R32tet32)
24. Malaria anticircumsporozoite antibodies in Dutch soldiers returning from sub-Saharan Africa